Literature DB >> 22320153

Using lean techniques to define the platelet (PLT) transfusion process and cost-effectiveness to evaluate PLT dose transfusion strategies.

William Riley1, Benjamin Smalley, Shelley Pulkrabek, Mary E Clay, Jeffrey McCullough.   

Abstract

BACKGROUND: Platelet (PLT) doses of 1.1 × 10(11), 2.2 × 10(11), and 4.4 × 10(11) /m(2) body surface area are equally effective in preventing bleeding. These different dose strategies involve different numbers of transfusions. We conducted a cost analysis of three separate PLT dose therapies. STUDY DESIGN AND METHODS: A process map of preparation and administration of a PLT transfusion identified 46 steps (23 steps in the blood bank and 23 steps on the care unit). Time studies were conducted for these 46 steps. Supply costs and personnel costs were estimated based on time studies. We conducted a cost analysis of three separate treatment regimes involving 16 transfusions per patient for the low-dose, 12 transfusions for medium-dose, and eight transfusions for high-dose regimes.
RESULTS: The time and the cost of the transfusion process for the blood bank were 32.41 minutes and $21.93 per unit, and for the patient care unit, 58.36 minutes and $57.71 per unit. The total cost for a course of PLT therapy per patient ranged from $4503.77 to $7014.59 for three different PLT doses. For a simulated bone marrow transplantation unit with 259 patients annually, there would be approximately a $700,000 difference among the clinically equivalent low-, medium-, and high-dose treatment options.
CONCLUSIONS: The overall cost of transfusion therapy is more influenced by the cost of the product than the cost of providing the transfusion. Depending on the cost adjustment by the supplier for different doses of PLTs, a low-dose transfusion strategy can be less costly.
© 2012 American Association of Blood Banks.

Entities:  

Mesh:

Year:  2012        PMID: 22320153     DOI: 10.1111/j.1537-2995.2011.03539.x

Source DB:  PubMed          Journal:  Transfusion        ISSN: 0041-1132            Impact factor:   3.157


  11 in total

1.  Financial impact of alternative approaches to reduce bacterial contamination of platelet transfusions.

Authors:  Seema Kacker; Evan M Bloch; Paul M Ness; Eric A Gehrie; Christi E Marshall; Parvez M Lokhandwala; Aaron A R Tobian
Journal:  Transfusion       Date:  2019-01-08       Impact factor: 3.157

Review 2.  Scratching the surface of allergic transfusion reactions.

Authors:  William J Savage; Aaron A R Tobian; Jessica H Savage; Robert A Wood; John T Schroeder; Paul M Ness
Journal:  Transfusion       Date:  2012-09-24       Impact factor: 3.157

Review 3.  Clinical effectiveness and comparative hospital costs of different platelet dose strategies.

Authors:  Tarek Bou Assi; Antoine Haddad; Elizabeth Baz
Journal:  Blood Transfus       Date:  2014-07       Impact factor: 3.443

4.  Comparison of a therapeutic-only versus prophylactic platelet transfusion policy for people with congenital or acquired bone marrow failure disorders.

Authors:  Asma Ashraf; Andreas V Hadjinicolaou; Carolyn Doree; Sally Hopewell; Marialena Trivella; Lise J Estcourt
Journal:  Cochrane Database Syst Rev       Date:  2016-09-01

5.  A FHIR Human Leukocyte Antigen (HLA) Interface for Platelet Transfusion Support.

Authors:  William J Gordon; Jane Baronas; William J Lane
Journal:  Appl Clin Inform       Date:  2017-06-07       Impact factor: 2.342

6.  The cost-effectiveness of platelet additive solution to prevent allergic transfusion reactions.

Authors:  Seema Kacker; Paul M Ness; William J Savage; Kevin D Frick; Jeffrey McCullough; Karen E King; Aaron A R Tobian
Journal:  Transfusion       Date:  2013-01-30       Impact factor: 3.157

Review 7.  The effect of platelet storage temperature on haemostatic, immune, and endothelial function: potential for personalised medicine.

Authors:  Susan M Shea; Kimberly A Thomas; Philip C Spinella
Journal:  Blood Transfus       Date:  2019-07       Impact factor: 3.443

Review 8.  Comparison of a therapeutic-only versus prophylactic platelet transfusion policy for people with congenital or acquired bone marrow failure disorders.

Authors:  Reem Malouf; Asma Ashraf; Andreas V Hadjinicolaou; Carolyn Doree; Sally Hopewell; Lise J Estcourt
Journal:  Cochrane Database Syst Rev       Date:  2018-05-14

9.  Cost implications of implementation of pathogen-inactivated platelets.

Authors:  Jeffrey McCullough; Dennis Goldfinger; Jed Gorlin; William J Riley; Harpreet Sandhu; Christopher Stowell; Dawn Ward; Mary Clay; Shelley Pulkrabek; Vera Chrebtow; Adonis Stassinopoulos
Journal:  Transfusion       Date:  2015-05-18       Impact factor: 3.157

10.  The argument(s) for lowering the US minimum required content of apheresis platelet components.

Authors:  Richard J Benjamin; Louis Katz; Richard R Gammon; Susan L Stramer; Eva Quinley
Journal:  Transfusion       Date:  2018-11-21       Impact factor: 3.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.